BR112015025392A2 - composição de vacina e método de utilização - Google Patents

composição de vacina e método de utilização

Info

Publication number
BR112015025392A2
BR112015025392A2 BR112015025392A BR112015025392A BR112015025392A2 BR 112015025392 A2 BR112015025392 A2 BR 112015025392A2 BR 112015025392 A BR112015025392 A BR 112015025392A BR 112015025392 A BR112015025392 A BR 112015025392A BR 112015025392 A2 BR112015025392 A2 BR 112015025392A2
Authority
BR
Brazil
Prior art keywords
vaccine composition
gla
combination
adjuvant
particular embodiment
Prior art date
Application number
BR112015025392A
Other languages
English (en)
Inventor
Ann Stillman Elizabeth
Van Nest Gary
Chui Ling Woo Jennifer
Tang Roderick
Lynn Lambert Stacie
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112015025392A2 publication Critical patent/BR112015025392A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "composição de vacina e método de utilização". é aqui descrita uma composição de vacina e métodos de ser utilizada. em uma modalidade, a composição de vacina inclui proteína rsv-f em combinação com um adjuvante. em uma modalidade mais particular, a composição de vacina inclui proteína f solúvel de rsv em combinação com um agonista de receptor tipo toll (tlr) lipídico. em uma modalidade mais particular, o adjuvante compreende glucopiranosil lipídio a (gla). em uma outra modalidade, o adjuvante compreende gla em uma emulsão óleo-em-água estável (gla-se).
BR112015025392A 2013-04-08 2014-04-04 composição de vacina e método de utilização BR112015025392A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809563P 2013-04-08 2013-04-08
PCT/US2014/032938 WO2014168821A1 (en) 2013-04-08 2014-04-04 Vaccine composition and method of use

Publications (1)

Publication Number Publication Date
BR112015025392A2 true BR112015025392A2 (pt) 2017-10-10

Family

ID=51689929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025392A BR112015025392A2 (pt) 2013-04-08 2014-04-04 composição de vacina e método de utilização

Country Status (13)

Country Link
US (1) US20160144021A1 (pt)
EP (1) EP2983708A4 (pt)
JP (1) JP2016516755A (pt)
KR (1) KR20150139954A (pt)
CN (1) CN105188748A (pt)
AU (1) AU2014251247A1 (pt)
BR (1) BR112015025392A2 (pt)
CA (1) CA2909077A1 (pt)
HK (2) HK1214138A1 (pt)
MX (1) MX2015013832A (pt)
RU (1) RU2015146762A (pt)
SG (1) SG11201507978XA (pt)
WO (1) WO2014168821A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
WO2016144675A1 (en) * 2015-03-06 2016-09-15 Medimmune, Llc Vaccine dose and use thereof
EP3518963A4 (en) * 2016-09-27 2020-06-10 ImmunoVaccine Technologies Inc. METHOD FOR USE OF B-CELL EPITOP COMPOSITIONS WITH LOW DOSAGE VOLUME FOR INDUCING AN ANTIBODY IMMUNE REACTION IN PERSONS
CN110352072A (zh) 2016-10-03 2019-10-18 马萨诸塞大学 用于免疫免疫前受试者以抵抗呼吸道合胞病毒(rsv)的方法
CN117843811A (zh) * 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CN116199750A (zh) * 2023-01-06 2023-06-02 吉林大学 一种核糖体蛋白s11及制备方法和在疫苗佐剂中的应用
CN118063569B (zh) * 2024-04-24 2024-08-30 上海金翌生物科技有限公司 一种幽门螺杆菌分泌蛋白及其在检测幽门螺杆菌中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089562A1 (en) * 2000-05-25 2001-11-29 Medimmune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
WO2003090685A2 (en) * 2002-04-24 2003-11-06 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2597439T3 (es) * 2007-12-24 2017-01-18 Id Biomedical Corporation Of Quebec Antígenos recombinantes del VSR
CA2766205A1 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
MA33449B1 (fr) * 2009-06-24 2012-07-03 Glaxosmithkline Biolog Sa Antigènes recombinants du vrs
ES2918381T3 (es) * 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
WO2013049342A1 (en) * 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
CN105431169B (zh) * 2012-03-22 2019-04-02 扬森疫苗与预防公司 抗rsv疫苗

Also Published As

Publication number Publication date
AU2014251247A1 (en) 2015-11-05
HK1214138A1 (zh) 2016-07-22
CN105188748A (zh) 2015-12-23
JP2016516755A (ja) 2016-06-09
MX2015013832A (es) 2016-06-10
US20160144021A1 (en) 2016-05-26
SG11201507978XA (en) 2015-10-29
CA2909077A1 (en) 2014-10-16
EP2983708A1 (en) 2016-02-17
RU2015146762A (ru) 2017-05-16
WO2014168821A1 (en) 2014-10-16
KR20150139954A (ko) 2015-12-14
EP2983708A4 (en) 2016-10-05
HK1221641A1 (zh) 2017-06-09

Similar Documents

Publication Publication Date Title
BR112015025392A2 (pt) composição de vacina e método de utilização
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
BR112012030552A2 (pt) composição imunogênica
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
BR112014006897A2 (pt) sistema de cabeça de fraturamento ajustável e câmara tubular
CL2018001007A1 (es) Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538).
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
BR112015027291A8 (pt) uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112015022934A8 (pt) esteróides neuroativos, composições e usos destes
CO6751288A2 (es) Composición antigénica de micobacteria
BRPI0510430A (pt) composições e métodos para vacinação mucosal
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BRPI0922695A2 (pt) Membro de suporte, sistema e método para suportar um membro alongado
BR112014006988A2 (pt) sistema de fraturamento ajustável
BR112015022210A8 (pt) formulações de anticorpo
MX2021015825A (es) Formulaciones de anticuerpos estables acuosas.
BR112015025709A2 (pt) monoterapia com gla para uso em tratamento de câncer
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
BR112015015864A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
TN2015000569A1 (en) Stable liquid formulation of amg 416 (velcalcetide)
BR112015016817A8 (pt) métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica
MX364800B (es) Tilmicosina de accion prolongada mejorada y el uso de la misma en el tratamiento del complejo respiratorio bovino (crb) y en el periodo de la vaca seca.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]